CN Patent

CN105102436B — 微晶二酮哌嗪组合物以及方法

Assigned to Mannkind Corp · Expires 2018-06-12 · 8y expired

What this patent protects

本发明公开了一种通过改进方法制备的DKP微晶，所述DKP微晶不会不可逆地自组装成微粒。所述微晶可通过雾化分散并通过喷雾干燥重新形成为具有球壳形态的颗粒。可通过对含有待整合到微晶二酮哌嗪颗粒中的组分的溶液进行喷雾干燥来将活性剂和赋形剂整合到所述颗粒中。特别地，所述微晶颗粒组合物适用于一种或多种肽、蛋白质、核酸和/或有机小分子的肺部药物递送。

USPTO Abstract

本发明公开了一种通过改进方法制备的DKP微晶，所述DKP微晶不会不可逆地自组装成微粒。所述微晶可通过雾化分散并通过喷雾干燥重新形成为具有球壳形态的颗粒。可通过对含有待整合到微晶二酮哌嗪颗粒中的组分的溶液进行喷雾干燥来将活性剂和赋形剂整合到所述颗粒中。特别地，所述微晶颗粒组合物适用于一种或多种肽、蛋白质、核酸和/或有机小分子的肺部药物递送。

Drugs covered by this patent

Patent Metadata

Patent number
CN105102436B
Jurisdiction
CN
Classification
—
Expires
2018-06-12
Drug substance claim
No
Drug product claim
No
Assignee
Mannkind Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.